First 3-Day Over-the-Counter Vaginal Yeast Infection Product Clears FDA Approval

Strategic Insights -

A significant advancement in the treatment of vaginal yeast infections has been achieved with the approval of FEMSTAT 3, an over-the-counter (OTC) treatment developed by the Procter & Gamble Company and Roche Holding Ltd. This product will be the first and only 3-day treatment brand available without a prescription, marking a significant shift in the treatment paradigm for millions of women suffering from this common condition.

Key Takeaways:

  • FEMSTAT 3 is a 3-day OTC treatment for vaginal yeast infections, cleared by the FDA for marketing.
  • The product contains the active ingredient butoconazole nitrate 2%, a proven antifungal agent.
  • FEMSTAT 3 has been shown to be as safe and effective as the leading 7-day OTC brand, Monistat 7, in clinical studies.
  • The 3-day treatment regimen may contribute to improved patient compliance and convenience.
  • Product benefits include a unique 5-gram prefilled disposable applicator and a 20-gram tube with three disposable cardboard applicators.
  • Recommended dosage is one applicatorful each day for three consecutive days, preferably at bedtime.
  • Between 1980 and 1990, the incidence of vulvovaginal candidiasis nearly doubled in the United States, with an annual occurrence of 13 million cases.
  • The U.S. OTC vaginal antifungal market is estimated at $260 million.
  • FEMSTAT 3 is the result of a prescription-to-OTC switch of the prescription products, FEMSTAT and FEMSTAT Prefill.
  • The product should not be used by pregnant women, women with diabetes, or those with a positive HIV test or AIDS.
  • FEMSTAT 3 should not be used in girls under 12 years of age.